{"name":"EirGenix, Inc.","slug":"eirgenix-inc","ticker":"","exchange":"","domain":"","description":"EirGenix, Inc. is a biopharmaceutical company focused on the development of biosimilar and innovative therapies primarily in the field of oncology. The company has a pipeline of five drug candidates, including biosimilars of Perjeta, which are currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EG12014","genericName":"EG12014","slug":"eg12014","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_3"}]}],"pipeline":[{"name":"EG12014","genericName":"EG12014","slug":"eg12014","phase":"phase_3","mechanism":"EG12014 is a monoclonal antibody targeting CD19.","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxObTN3R1ZmTjJIbjNzQkFDeFBJQ250bnc0MjV5TURWamtOMkNudklJVFE2WU9waW9rdGRkdUhaQWlnNzhLemw1TVdJRnhOcm1FTGowemdtT2R4NzlpdUZZVWFXZndsbUVOaWRLWDNqVURaWVVfNjJiUWVINkkzR3N0bWdOUllXV3ZhTU1wMXRpRXp6MnF2Z2Iwb2szcXNXSVRYWGlyWXE5c1ZrYjNzLWgxZWc0U0U0YU9lTE9fT1Z4WDNpNk15STRmY05ZVExOY3RSdDVNbVJNYmY0SVNTTzNvNjdCWHRPZXlVVVdZV2hNMENzOUdMcU1MUy1YVGkzcHRLT2paTjR6anhyV1p3b0ZaTV9FOU5mamwxeFYyRzY3ZDBscEtu?oc=5","date":"2026-03-17","type":"trial","source":"StreetInsider","summary":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - StreetInsider","headline":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPaWlhNnByTWJCbE9odXZ4VFNTTjlXZGJEZHdINFR0dXFHY0RfQkdIWEpEbWhPRTdQV1EwLU1wSFpYU2tvcHpTYnBOVDNOS0dvcVdOd0tLMk0tUmFjTkJRTjVHSTRucm1RRGltLWVNalZ6dzVwVC0tVlRXcUxfUmF0bmhjUEM3eVBad2lieWNxODBQRmc4TkE?oc=5","date":"2026-02-25","type":"pipeline","source":"The Pharma Letter","summary":"Sandoz delivers strong full-year 2025 results - The Pharma Letter","headline":"Sandoz delivers strong full-year 2025 results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQUVdoZlhidnJ3aU0weU90VE56S1E0N29LNk9hVmhRWmZ0bGtVOFpxYWRaOUxMZ1Y1MWJBTGxrYURUbmM3X2txNUVuVkRJYjhMV0o4dXluV2NxY2Z1ZkxVb2EtczhsYVFMc29QeXIzeUJjTGhtY3VWS3ppMXVFY1h6SU8xdXpMc3lEMTR3?oc=5","date":"2026-02-03","type":"pipeline","source":"geneonline.com","summary":"Taiwan’s Biotech Leaders Double Down on AI and US Manufacturing: Inside Bora and EirGenix’s Strategic Roadmaps - geneonline.com","headline":"Taiwan’s Biotech Leaders Double Down on AI and US Manufacturing: Inside Bora and EirGenix’s Strategic Roadmaps","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcVUwWGVNZlRTc3ZCY2pWcm9idm1MTm1DanI3ZEdFYkY2MG9iRUNSRzFUU2ZTZExXa0o1WUcxR1lHa0V2SERzVmE1d3NNTE53UHlQU0dsOFdjcnQxa2ctTXY2SzN4WUdBZlMtUFpYdnJtcC1lZ05CLU1uX2VuSTZzdHcyRDVMMkZqeDNwaTh6WENITHgtWjZXekw1aXc2ZG0zRVd5czR0QzlVdTF2dnZfVUZjUVVkd283Vndj?oc=5","date":"2025-12-29","type":"deal","source":"Contract Pharma","summary":"EirGenix Licenses Transcenta’s HiCB Platform to Improve Process Efficiency - Contract Pharma","headline":"EirGenix Licenses Transcenta’s HiCB Platform to Improve Process Efficiency","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNeWpHYkNvcW9xTEYySDZpMU9mVndHa2hmZmlPUDJGMjdwblpXTU05cExCc0h1TTBRd2l2dU5fSHNxZ3UxaGVEVUgyTWpSQ2Y3RlF6NG5LN01DTDM0WVA1b3hYc2xZQXhIUFVHQ09XeUVJemQ5NTUwcEZ4Nnk3dlUyVG5iWTVxeVBBVmI4OTliZi1sYmpWNFNsY2FyX3VsRWdETklrVm5DMjJNTEk3QVc2RzdHNA?oc=5","date":"2025-11-14","type":"deal","source":"Drug Store News","summary":"Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab - Drug Store News","headline":"Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNMzBwWHdiczNYWTZKdDdUOFlXOXlrMjEtXzNYWnJkNFhhU005TTlxZDZXTlZsV0labDFRck5LX3FZUEVZTXpMNG4ybkFLdWFWMGlJaVFaRzJ3UEFFRUpiQVUzOFNGUk9DVmhqUWZhUG1DY3I4cUlmV0RMdUlaaFFvTFZTV1FoeFRzOU9LVVhCb0I3Z0N5UWNFamd0cmJjV1M0Q21VcWZ1LTBuMV93VnE3aA?oc=5","date":"2025-11-12","type":"deal","source":"Sandoz","summary":"Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab - Sandoz","headline":"Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPRlQxWnlRemJDckdSS19DcEJ5dDA0LTNNQXE1SHo1dlE4eUI5aVR1alIzd25lZXpXTms1amFiMkN3MkdibDVYM1dRUkFVRDBRTVZ2MVI0Ylh4bXdkcFFrWXpkYXVUenRTeC1YVVQxOG9rWm9RV2dDbHd6c3lobTRxTXNfdVZ2Z1Y0Nzl4LUxRYUVseHZoVGVWX0dpM0I4NFFMck5wcA?oc=5","date":"2024-04-05","type":"regulatory","source":"Generics and Biosimilars Initiative","summary":"EMA recommends approval of trastuzumab biosimilar Herwenda - Generics and Biosimilars Initiative","headline":"EMA recommends approval of trastuzumab biosimilar Herwenda","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQMUc5Yk5tdkZrMXBfaGxOV3Y1RFZ5VlcxQllfUnIxLXdzV2ZMeWMzRHJ2RHZ4aHowZU5yVVpNTEV0NlBISzVTSGhzN0laaWF4d18zTklmV3JkVVh1VG14S252RGExV3pIdXpiMy1ad2lDd3pCaUVsZzJVUlBfaE1qRzFtTmFBSDMxZnhETHM4SlJMRFZvb3U1b1lrVV80NUQtemFCbkdUb1ZYSGxxWlpWVXBEcE1nUWJVMmNYYlh4OUtfcER3RTRHeDRSRQ?oc=5","date":"2023-09-18","type":"patent","source":"Novartis","summary":"Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab - Novartis","headline":"Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOQ2M0VUtCRXpYdEVZWHFOdzNuTW5HNFBuczRBamQ3MDczQTV6S1RnZzNROTRwTXlOTnNLd0w2blBNclhiMUxyRHFsS0FIMjVMS3hjUV90QlJRWHZJbDNJWFIweURmSHBfVGxvQ3lDQlN6bE83b1pWS2NGRzREdmxsU3phZ0xlSERFVkxRMEJWd1QwZDZ0N2lhWXJBZ2pTN0NjSXU3NUZGZEpnZmNkYlBSMTBqNEpWd3U1UWo0eQ?oc=5","date":"2021-03-25","type":"patent","source":"BioSpectrum Asia","summary":"EirGenix's proposed Biosimilar 'Trastuzumab' shows positive Ph 3 results - BioSpectrum Asia","headline":"EirGenix's proposed Biosimilar 'Trastuzumab' shows positive Ph 3 results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQWWYzMkE4SnphSHAzbWNwYjBHX0ZxVTZnM2JCS19Wc0NDLXY4Ukx4MVVJSzRsNDJqal9PUjJvc01EdklUcHZyMTJNUHR5Z1J5Z05UdVBoVGQxd0haZUpmN1B6cy11SzFiMjFDX05qZktZOE5aZHQ3N2I3WDR6SXVVMGo2ZnRoNEJMZHNFR1d0aXNoMThrU0xJcUMzYw?oc=5","date":"2019-02-05","type":"pipeline","source":"Pharmaceutical Technology","summary":"Eirgenix Protein Drug Production Plant, Zhubei, Taiwan - Pharmaceutical Technology","headline":"Eirgenix Protein Drug Production Plant, Zhubei, Taiwan","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}